1 / 19

PCSK9 Loss-of-function Mutations

PCSK9 Loss-of-function Mutations. PCSK9-Mediated Degradation of LDL-R. Evolution of Therapeutic Monoclonal Antibodies. Effect of PCSK9 Inhibitors on LDL-C in Heterozygous FH. DESCARTES % Change in LDL-C From Baseline at Week 52 in Patients With Hypercholesterolemia.

alika-tyler
Download Presentation

PCSK9 Loss-of-function Mutations

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PCSK9 Loss-of-function Mutations

  2. PCSK9-Mediated Degradation of LDL-R

  3. Evolution of Therapeutic Monoclonal Antibodies

  4. Effect of PCSK9 Inhibitors on LDL-C in Heterozygous FH

  5. DESCARTES% Change in LDL-C From Baseline at Week 52 in Patients With Hypercholesterolemia

  6. GAUSS-1% Change in LDL-C From Baseline at Week 12 in Statin-Intolerant Patients

  7. Effect of PCSK9 Monoclonal Antibodies on ApoB and Lp(a)

  8. Role of apoB

  9. How Low Is Too Low?

  10. PCSK9 CV Outcomes Trials

  11. TESLATrial Evaluating PCSK9 Antibody in Homozygous FH

  12. Abbreviations

  13. Abbreviations (cont)

  14. References

  15. References (cont)

  16. References (cont)

More Related